Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + celecoxib
- Development stage
- Unknown
- Lead developer
- Tel Aviv Sourasky Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of rosuvastatin, an HMG-CoA reductase inhibitor (statin), and celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. It was investigated by the Tel-Aviv Sourasky Medical Center for the treatment and prevention of acute lung injury (ALI) following blunt thoracic trauma and lung contusion. The rationale for this combination is to leverage the pleiotropic anti-inflammatory and antioxidant properties of statins alongside the prostaglandin-inhibiting effects of COX-2 inhibitors to synergistically reduce the inflammatory burden and pulmonary damage associated with chest trauma. In clinical trial settings, the therapy was administered orally to evaluate its efficacy in reducing clinical parameters of ALI and inflammatory mediator levels in the serum and bronchoalveolar space.
- Other names
- Combined therapy-Tel-Aviv Sourasky Medical Center-acute lung injuryRosuvastatin and Celecoxib combinationStatins and Celecoxib in Blunt Chest Trauma
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on rosuvastatin + celecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + celecoxib.